Surgical Innovations - New LTIP & Grant of Options
RNS Number : 3418J
Surgical Innovations Group PLC
28 November 2025
Surgical Innovations Group plc
("Surgical Innovations", the "Company", or the "Group")
New LTIP & Grant of Options
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces the establishment of a new Long Term Incentive Plan ("2025 LTIP") for certain executive directors and employees in order to incentivise them in a manner that aligns with the interests of the Company's shareholders.
New LTIP
Under the terms of the 2025 LTIP, the Company has awarded nil cost share options (the "Options") over a total of 16,086,955 ordinary shares of 1 pence each in the Company ("Ordinary Shares") including to certain persons discharging managerial responsibilities ("PDMRs") as set out below.
The Options may be exercised at nil cost and are subject to performance criteria relating to revenue growth, EBIT growth and total shareholder returns alongside continuous employment with the Company for a period of three years ending on 26th November 2028.
The following PDMRs have been awarded Options:
| PDMRs | Role | No. of Options awarded | Total Options held post award |
| David Marsh | Chief Executive Officer | 9,130,434 | 9,130,434 |
| Brent Greetham | Chief Financial Officer | 6,956,521 | 6,956,521 |
| Surgical Innovations Group plc | www sigroupplc com | ||
| David Marsh, CEO | Tel: 0113 230 7597 | ||
| Brent Greetham, CFO | |||
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
| Alex Bond / Oliver Platts | |||
| Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 orsi@walbrookpr.com | ||
| Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | 1. David Marsh 2. Brent Greetham | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | 1. Chief Executive Officer 2. Chief Financial Officer | ||||
| b) | Initial notification/ Amendment | Initial Notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Surgical Innovations Group plc | ||||
| b) | LEI | 2138004GHGUH3HUZE156 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1p GB0004016704 | ||||
| b) | Nature of the transactions | Grant of options | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A N/A | ||||
| e) | Date of the transaction | 27 November 2025 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
Recent news on Surgical Innovations
See all newsBrief: Surgical Innovations Says Trading In The First Half Of The Year Was Broadly Flat
UK's Surgical Innovations H1 revenue flat, EBITDA drops on Europe and US headwinds
Brief: Surgical Innovations H1 Revenue GBP 6.019 Million
Surgical Innovations - Half-year Report
Brief: Surgical Innovations Group's CEO David Marsh To Step Down